$8.73 Billion is the total value of Bellevue Group AG's 266 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ADBE | Exit | ADOBE SYSTEMS INCORPORATED | $0 | – | -1,100 | -100.0% | -0.01% | – |
| HTHT | Exit | HUAZHU GROUP LTDsponsored ads | $0 | – | -13,500 | -100.0% | -0.01% | – |
| VAR | Exit | VARIAN MED SYS INC | $0 | – | -4,100 | -100.0% | -0.01% | – |
| SNY | Exit | SANOFIsponsored adr | $0 | – | -57,000 | -100.0% | -0.04% | – |
| NUVA | Exit | NUVASIVE INC | $0 | – | -82,100 | -100.0% | -0.06% | – |
| IART | Exit | INTEGRA LIFESCIENCES HLDGS C | $0 | – | -122,426 | -100.0% | -0.08% | – |
| AKCA | Exit | AKCEA THERAPEUTICS INC | $0 | – | -340,264 | -100.0% | -0.08% | – |
| GTHX | Exit | G1 THERAPEUTICS INC | $0 | – | -721,925 | -100.0% | -0.12% | – |
| SGEN | Exit | SEATTLE GENETICS INC | $0 | – | -46,600 | -100.0% | -0.13% | – |
| HMSY | Exit | HMS HLDGS CORP | $0 | – | -916,984 | -100.0% | -0.30% | – |
| LVGO | Exit | LIVONGO HEALTH INC | $0 | – | -203,329 | -100.0% | -0.39% | – |
| SGMO | Exit | SANGAMO THERAPEUTICS INC | $0 | – | -3,850,000 | -100.0% | -0.50% | – |
| MYOK | Exit | MYOKARDIA INC | $0 | – | -1,128,400 | -100.0% | -2.13% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- BB Biotech AG #1
- Bellevue Asset Management AG #2
- Bellevue Asset Management (UK) Ltd. #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.